title: A2A adenosine receptor agonists reduce both high-palatability and low-palatability food intake in female rats.
abstract: The present study examined the effect of two A(2A) adenosine receptor (AR) agonists, CGS 21680 and VT 7, on high-palatability food (HPF) intake in a model of binge eating in sated rats and on low-palatability food (LPF) intake in food-deprived rats. Binge eating was induced in female rats by three 8-day cycles of food restriction/refeeding, followed by acute stress. Two groups of rats were used: NR+NS rats normally fed and not stressed and R+S rats exposed to cycles of food restriction/refeeding and then stressed. R+S rats had higher intake of HPF than the NR+NS controls. The two A(2A)AR agonists were tested at doses of 0.1 and 0.05 mg/kg intraperitoneally; VT 7 did not modify locomotor activity at either dose, whereas CGS 21680 only slightly reduced it at the higher dose tested. The injection of 0.1 mg/kg of both agonists markedly reduced HPF intake both in R+S and in NR+NS rats. The dose of 0.05 mg/kg was inactive. CGS 21680 and VT 7, 0.1 mg/kg, also reduced the standard LPF intake in 24 h food-deprived rats; however, they did not reduce water intake, indicating that their effect on food intake is selective. The dose of 0.05 mg/kg was inactive. Thus, A(2A)AR agonists exert a rather general effect on food intake, inhibiting both HPF intake in sated rats and LPF intake in food-deprived rats. They may potentially be useful pharmacological agents to control binge-related eating disorders and to reduce food overconsumption associated with obesity.
authors: School of Pharmacy, Pharmacology Unit, University of Camerino, Camerino, Italy. mariavittoria.micioni@unicam.it
authors: Maria V
authors: MV
authors: Micioni Di Bonaventura
authors: Carlo
authors: C
authors: Cifani
authors: Catia
authors: C
authors: Lambertucci
authors: Rosaria
authors: R
authors: Volpini
authors: Gloria
authors: G
authors: Cristalli
authors: Maurizio
authors: M
authors: Massi
mesh_terms: D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058908:Adenosine A2 Receptor Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001067:Appetite Depressants / Q000008:administration & dosage / Q000627:therapeutic use*; D001069:Appetite Regulation / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects; D056912:Binge-Eating Disorder / Q000188:drug therapy*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D002149:Energy Intake / Q000187:drug effects; D005247:Feeding Behavior / Q000187:drug effects*; D005260:Female; D005518:Food Preferences; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism; D010627:Phenethylamines / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D043705:Receptor, Adenosine A2A / Q000737:chemistry / Q000378:metabolism*; D012528:Satiety Response / Q000187:drug effects; D013872:Thionucleosides / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: C572126:5'-N-ethylcarboxamido-2-(2-phenethylthio)adenosine; D058908:Adenosine A2 Receptor Agonists; D001067:Appetite Depressants; D009419:Nerve Tissue Proteins; D010627:Phenethylamines; D043705:Receptor, Adenosine A2A; D013872:Thionucleosides; C061282:2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine; D000241:Adenosine